Cover Image
市場調查報告書

抗性綠色膿菌感染疾病:開發平台分析

Resistant Pseudomonas aeruginosa Infections - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 321921
出版日期 內容資訊 英文 62 Pages
訂單完成後即時交付
價格
Back to Top
抗性綠色膿菌感染疾病:開發平台分析 Resistant Pseudomonas aeruginosa Infections - Pipeline Review, H2 2016
出版日期: 2016年09月28日 內容資訊: 英文 62 Pages
簡介

綠膿菌對宿主抵抗力弱的患者而言是造成感染的重要原因。這個菌種具有對各種抗生物質急速產生抗藥性的能力。此外更是入院一週以上的患者最常分離出的病原體。症狀有肺炎、發燒、疲勞感、會發癢的疹子、出血性潰瘍、頭痛等。危險因子有高齡化及身體衰弱免疫系統低落等。

本報告提供抗性綠色膿菌感染疾病的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您企業和研究機關開發中的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊,以及最新的新聞和發表等訊息。

簡介

  • 調查範圍

抗性綠色膿菌感染疾病:開發平台分析 概要

治療藥的開發

  • 開發中產品;概要
  • 開發中產品;比較分析

企業開發中的治療藥

大學/機關研究中的治療藥

開發中產品概況

  • 臨床階段的產品
  • 初期階段的產品

企業開發中的產品

大學/機關研究中的產品

治療藥的開發企業

  • Achaogen Inc.
  • AstraZeneca Plc
  • Biolytics Pharma
  • CSA Biotechnologies LLC
  • LegoChem Biosciences, Inc
  • Melinta Therapeutics, Inc
  • Phico Therapeutics Limited
  • Phylogica Limited
  • 鹽野義製藥
  • Zambon Company S.p.A.

治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • ACHN-975 Prodrug
  • 綠色膿菌感染疾病生技藥品
  • CSA-13
  • G-10
  • LCB-010200
  • LCB-100200
  • 革蘭氏陰性菌感染疾病的單株抗體
  • PT-3.33
  • RXP-763
  • RXP-766
  • RXP-770
  • RXP-792
  • RXP-793
  • RXP-808
  • RXP-873
  • S-649266
  • 多重抗藥性菌感染疾病小分子
  • 抗性綠色膿菌感染疾病用小分子
  • 革蘭氏陰性菌感染疾病LpxC抑制劑
  • ZP-046

最近的開發平台趨勢

暫停中的計劃

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8491IDB

Summary

Global Markets Direct's, 'Resistant Pseudomonas aeruginosa Infections - Pipeline Review, H2 2016', provides an overview of the Resistant Pseudomonas aeruginosa Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Resistant Pseudomonas aeruginosa Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Resistant Pseudomonas aeruginosa Infections and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Resistant Pseudomonas aeruginosa Infections
  • The report reviews pipeline therapeutics for Resistant Pseudomonas aeruginosa Infections by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Resistant Pseudomonas aeruginosa Infections therapeutics and enlists all their major and minor projects
  • The report assesses Resistant Pseudomonas aeruginosa Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Resistant Pseudomonas aeruginosa Infections

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Resistant Pseudomonas aeruginosa Infections
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Resistant Pseudomonas aeruginosa Infections pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Resistant Pseudomonas aeruginosa Infections Overview
  • Therapeutics Development
    • Pipeline Products for Resistant Pseudomonas aeruginosa Infections - Overview
    • Pipeline Products for Resistant Pseudomonas aeruginosa Infections - Comparative Analysis
  • Resistant Pseudomonas aeruginosa Infections - Therapeutics under Development by Companies
  • Resistant Pseudomonas aeruginosa Infections - Therapeutics under Investigation by Universities/Institutes
  • Resistant Pseudomonas aeruginosa Infections - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Resistant Pseudomonas aeruginosa Infections - Products under Development by Companies
  • Resistant Pseudomonas aeruginosa Infections - Products under Investigation by Universities/Institutes
  • Resistant Pseudomonas aeruginosa Infections - Companies Involved in Therapeutics Development
    • Achaogen Inc.
    • AstraZeneca Plc
    • Biolytics Pharma
    • CSA Biotechnologies LLC
    • LegoChem Biosciences, Inc
    • Melinta Therapeutics, Inc
    • Phico Therapeutics Limited
    • Shionogi & Co., Ltd.
    • Zambon Company S.p.A.
  • Resistant Pseudomonas aeruginosa Infections - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • ACHN-975 Prodrug - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Biologic for Pseudomonas Aeruginosa Infection - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CSA-13 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • G-10 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IMT-504 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LCB-010200 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LCB-100200 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibodies for Gram-Negative Bacterial Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit PcrV for Resistant Pseudomonas aeruginosa Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PT-3.33 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RXP-763 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RXP-766 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RXP-770 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RXP-792 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RXP-793 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RXP-808 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RXP-873 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • S-649266 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Resistant Pseudomonas aeruginosa Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit LpxC for Gram-Negative Bacterial Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ZP-046 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Resistant Pseudomonas aeruginosa Infections - Dormant Projects
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Resistant Pseudomonas aeruginosa Infections, H2 2016
  • Number of Products under Development for Resistant Pseudomonas aeruginosa Infections - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Resistant Pseudomonas aeruginosa Infections - Pipeline by Achaogen Inc., H2 2016
  • Resistant Pseudomonas aeruginosa Infections - Pipeline by AstraZeneca Plc, H2 2016
  • Resistant Pseudomonas aeruginosa Infections - Pipeline by Biolytics Pharma, H2 2016
  • Resistant Pseudomonas aeruginosa Infections - Pipeline by CSA Biotechnologies LLC , H2 2016
  • Resistant Pseudomonas aeruginosa Infections - Pipeline by LegoChem Biosciences, Inc, H2 2016
  • Resistant Pseudomonas aeruginosa Infections - Pipeline by Melinta Therapeutics, Inc, H2 2016
  • Resistant Pseudomonas aeruginosa Infections - Pipeline by Phico Therapeutics Limited, H2 2016
  • Resistant Pseudomonas aeruginosa Infections - Pipeline by Shionogi & Co., Ltd., H2 2016
  • Resistant Pseudomonas aeruginosa Infections - Pipeline by Zambon Company S.p.A., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Resistant Pseudomonas aeruginosa Infections - Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for Resistant Pseudomonas aeruginosa Infections, H2 2016
  • Number of Products under Development for Resistant Pseudomonas aeruginosa Infections - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top